One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
There is no diagnosis of exclusion in rheumatology
Michael Putman, Jayshil J Patel, Anisha Dua
doi : 10.1093/rheumatology/keac278
Rheumatology, Volume 62, Issue 1, January 2023, Pages 1–2
Challenging wisely: how to move beyond ‘1 mg/kg then taper’
Shannon Tai, Natalie Anumolu, Michael Putman
doi : 10.1093/rheumatology/keac221
Rheumatology, Volume 62, Issue 1, January 2023, Pages 3–6
Health inequalities across patients with early inflammatory arthritis of different ethnicities: what could be the driving factors?
Sytske Anne Bergstra
doi : 10.1093/rheumatology/keac383
Rheumatology, Volume 62, Issue 1, January 2023, Pages 7–8
Frequency of AA amyloidosis has decreased in Behçet’s syndrome: a retrospective study with long-term follow-up and a systematic review: Amyloidosis in Behçet’s syndrome
Guzin Karatemiz, Sinem Nihal Esatoglu, Mert Gurcan, Yesim Ozguler, Sebahattin Yurdakul, Vedat Hamuryudan, Izzet Fresko, Melike Melikoglu, Emire Seyahi, Serdal Ugurlu, Huri Ozdogan, Hasan Yazici, Gulen Hatemi
doi : 10.1093/rheumatology/keac223
Rheumatology, Volume 62, Issue 1, January 2023, Pages 9–18
A decline in the frequency of AA amyloidosis secondary to RA and infectious diseases has been reported. We aimed to determine the change in the frequency of AA amyloidosis in our Behçet’s syndrome (BS) patients and to summarize the clinical characteristics of and outcomes for our patients, and also those identified by a systematic review.
A genomic meta-analysis of clinical variables and their association with intrinsic molecular subsets in systemic sclerosis
Jennifer M Franks, Diana M Toledo, Viktor Martyanov, Yue Wang, Suiyuan Huang, Tammara A Wood, Cathie Spino, Lorinda Chung, Christopher P Denton, Emma Derrett-Smith, Jessica K Gordon, Robert Spiera, Robyn Domsic, Monique Hinchcliff, Dinesh Khanna, Michael L Whitfield
doi : 10.1093/rheumatology/keac344
Rheumatology, Volume 62, Issue 1, January 2023, Pages 19–28
Four intrinsic molecular subsets (inflammatory, fibroproliferative, limited, normal-like) have previously been identified in SSc and are characterized by unique gene expression signatures and pathways.
Women in rheumatology: major contributions and key discoveries of the twentieth century
Alla Ishchenko, Silvia Scriffignano, Laura Coates
doi : 10.1093/rheumatology/keac376
Rheumatology, Volume 62, Issue 1, January 2023, Pages 29–34
In the twentieth century, rheumatology saw an exponential growth. Discoveries in the pathophysiology of rheumatic diseases, progress in research methodology and novel treatments cardinally changed the natural course of rheumatic diseases and revolutionized patient management.
Controversies in rheumatology: maintenance therapy with low-dose glucocorticoids in rheumatoid arthritis
Frank Buttgereit, Tore K Kvien
doi : 10.1093/rheumatology/keac355
Rheumatology, Volume 62, Issue 1, January 2023, Pages 35–41
Since the beginning of the use of glucocorticoids in clinical medicine, the risk–benefit ratio of these still very important drugs has been debated. There is no doubt that they produce many desirable therapeutic effects quickly and reliably.
Activation of circulating monocytes by low-density lipoprotein—a risk factor for osteoarthritis?
Nik N L Kruisbergen, Yvonne van Gemert, Arjen B Blom, Martijn H J van den Bosch, Peter L E M van Lent
doi : 10.1093/rheumatology/keac359
Rheumatology, Volume 62, Issue 1, January 2023, Pages 42–51
Synovial macrophages are key mediators of OA pathology, and skewing of macrophage phenotype in favour of an M1-like phenotype is thought to underlie the chronicity of synovial inflammation in OA.
Exploring discordance between Health Literacy Questionnaire scores of people with RMDs and assessment by treating health professionals
Mark M Bakker, Polina Putrik, Cédric Dikovec, Jany Rademakers, Harald E Vonkeman, Marc R Kok, Hanneke Voorneveld-Nieuwenhuis, Sofia Ramiro, Maarten de Wit, Rachelle Buchbinder, Roy Batterham, Richard H Osborne, Annelies Boonen
doi : 10.1093/rheumatology/keac248
Rheumatology, Volume 62, Issue 1, January 2023, Pages 52–64
We studied discordance between health literacy of people with rheumatic and musculoskeletal diseases (RMDs) and assessment of health literacy by their treating health professionals, and explored whether discordance is associated with the patients’ socioeconomic background.
COVID-19 vaccination-related adverse events among autoimmune disease patients: results from the COVAD study
Parikshit Sen, Naveen Ravichandran, Arvind Nune, James B Lilleker, Vishwesh Agarwal, Sinan Kardes, Minchul Kim, Jessica Day, Marcin Milchert, Tamer Gheita, Babur Salim, Tsvetelina Velikova, Abraham Edgar Gracia-Ramos, Ioannis Parodis, Albert Selva O’Callaghan, Elena Nikiphorou, Tulika Chatterjee, Ai Lyn Tan, Lorenzo Cavagna, Miguel A Saavedra, Samuel Katsuyuki Shinjo, Nelly Ziade, Johannes Knitza, Masataka Kuwana, Oliver Distler, Hector Chinoy, Vikas Agarwal, Rohit Aggarwal, Latika Gupta, COVAD Study Group
doi : 10.1093/rheumatology/keac305
Rheumatology, Volume 62, Issue 1, January 2023, Pages 65–76
COVID-19 vaccines have been proven to be safe in the healthy population. However, gaps remain in the evidence of their safety in patients with systemic autoimmune and inflammatory disorders (SAIDs).
COVID-19 infection and hospitalization risk according to vaccination status and DMARD treatment in patients with rheumatoid arthritis
René Cordtz, Salome Kristensen, Rasmus Westermann, Kirsten Duch, Fiona Pearce, Jesper Lindhardsen, Christian Torp-Pedersen, Mikkel P Andersen, Lene Dreyer
doi : 10.1093/rheumatology/keac241
Rheumatology, Volume 62, Issue 1, January 2023, Pages 77–88
The objectives of this study were to investigate the incidence of COVID-19 hospitalization in unvaccinated and vaccinated patients with RA compared with matched controls, and in patients with RA according to DMARD treatment.
Comparison of drug retention of TNF inhibitors, other biologics and JAK inhibitors in RA patients who discontinued JAK inhibitor therapy
Andrea Amstad, Eleftherios Papagiannoulis, Almut Scherer, Andrea Rubbert-Roth, Axel Finckh, Ruediger Mueller, Jean Dudler, Burkhard M?ller, Peter M Villiger, Martin M P Schulz, Diego Kyburz
doi : 10.1093/rheumatology/keac285
Rheumatology, Volume 62, Issue 1, January 2023, Pages 89–97
JAK Inhibitors (JAKi) are recommended DMARDs for patients with moderate-to-severe RA who failed first-line therapy with methotrexate. There is a lack of data allowing an evidence-based choice of subsequent DMARD therapy for patients who had discontinued JAKi treatment.
Patient Experienced Symptom State in rheumatoid arthritis: sensitivity to change in disease activity and impact
Cati? Duarte, Tore K Kvien, Joe Sexton, Eduardo Santos, Maarten de Wit, Laure Gossec, Jose A P da Silva
doi : 10.1093/rheumatology/keac257
Rheumatology, Volume 62, Issue 1, January 2023, Pages 98–107
The Patient Experienced Symptom State (PESS) is a single-question, patient-reported outcome that is validated to assess global disease impact in RA. This study addresses its sensitivity to change, and reliability.
New indicator for discordance between patient-reported and traditional disease activity outcomes in patients with early rheumatoid arthritis
Sofia Pazmino, Anik? Lovik, Annelies Boonen, Diederik De Cock, Veerle Stouten, Johan Joly, Michaël Doumen, Delphine Bertrand, René Westhovens, Patrick Verschueren
doi : 10.1093/rheumatology/keac213
Rheumatology, Volume 62, Issue 1, January 2023, Pages 108–115
To unravel disease impact in early RA by separately quantifying patient-reported (PRF), clinical (CF) and laboratory (LF) factors. We propose a new indicator, the discordance score (DS), for early identification and prediction of patient’s unmet needs and of future achievement of sustained remission (SR) and RA-related quality of life (QoL).
Musculoskeletal ultrasound may narrow the gap between patients and physicians in the assessment of rheumatoid arthritis disease activity
Alberto Floris, Davide Rozza, Anna Zanetti, Greta Carrara, Emanuela Bellis, Alberto Cauli, Annamaria Iagnocco, Carlo Alberto Scirè, Matteo Piga, STARTER investigators
doi : 10.1093/rheumatology/keac255
Rheumatology, Volume 62, Issue 1, January 2023, Pages 116–123
To investigate the association between patient–physician discordance in the assessment of disease activity and residual US synovitis/tenosynovitis in a cohort of patients with RA in clinical remission.
ACPA-negative and ACPA-positive RA patients achieving disease resolution demonstrate distinct patterns of MRI-detected joint-inflammation
Marloes Verstappen, Xanthe M E Matthijssen, Sean E Connolly, Michael A Maldonado, Tom W J Huizinga, Annette H M van der Helm-van Mil
doi : 10.1093/rheumatology/keac294
Rheumatology, Volume 62, Issue 1, January 2023, Pages 124–134
Although sustained DMARD-free remission (SDFR; sustained absence of clinical-synovitis after DMARD-discontinuation) is increasingly achievable in RA, prevalence differs between ACPA-negative (40%) and ACPA-positive RA (5–10%).
The impact of psoriasis on the clinical characteristics, disease burden and treatment patterns of peripheral spondyloarthritis
Tugba Izci Duran, Murat Torgutalp, Valeria Rios Rodriguez, Fabian Proft, Clementina L?pez-Medina, Maxime Dougados, Denis Poddubnyy
doi : 10.1093/rheumatology/keac235
Rheumatology, Volume 62, Issue 1, January 2023, Pages 135–146
To evaluate the clinical characteristics, disease burden, and treatment patterns of peripheral spondyloarthritis (pSpA) patients with and without psoriasis using data from the ASAS-perSpA study.
Predicted and actual 2-year structural and pain progression in the IMI-APPROACH knee osteoarthritis cohort
Eefje M van Helvoort, Mylène P Jansen, Anne C A Marijnissen, Margreet Kloppenburg, Francisco J Blanco, Ida K Haugen, Francis Berenbaum, Anne-Christine C Bay-Jensen, Christoph Ladel, Agnes Lalande, Jonathan Larkin, John Loughlin, Ali Mobasheri, Harrie H Weinans, Pawel Widera, Jaume Bacardit, Paco M J Welsing, Floris P J G Lafeber
doi : 10.1093/rheumatology/keac292
Rheumatology, Volume 62, Issue 1, January 2023, Pages 147–157
The IMI-APPROACH knee osteoarthritis study used machine learning (ML) to predict structural and/or pain progression, expressed by a structural (S) and pain (P) predicted-progression score, to select patients from existing cohorts. This study evaluates the actual 2-year progression within the IMI-APPROACH, in relation to the predicted-progression scores.
Trends in risk factor control in patients with gout: data from the National Health and Nutrition Examination Survey, 2007–2018
Likang Li, Junzhang Tian, Ruoting Wang, Jonathan D Adachi, Bo Chen, Hongying Qu, Guowei Li
doi : 10.1093/rheumatology/keac254
Rheumatology, Volume 62, Issue 1, January 2023, Pages 158–168
To explore trends in risk factor control (hypertension, diabetes mellitus, hyperlipidaemia) in patients with gout and medication use among those whose risk factor control targets were not achieved.
Worse outcomes linked to ethnicity for early inflammatory arthritis in England and Wales: a national cohort study
Maryam A Adas, Sam Norton, Sathiyaa Balachandran, Edward Alveyn, Mark D Russell, Thomas Esterine, Paul Amlani-Hatcher, Sarah Oyebanjo, Heidi Lempp, Joanna Ledingham, Kanta Kumar, James B Galloway, Shirish Dubey
doi : 10.1093/rheumatology/keac266
Rheumatology, Volume 62, Issue 1, January 2023, Pages 169–180,
To assess variability in care quality and treatment outcomes across ethnicities in early inflammatory arthritis (EIA).
Low-dose glucocorticoids withdrawn in systemic lupus erythematosus: a desirable and attainable goal
Lanlan Ji, Dai Gao, Yanjie Hao, Hong Huang, Yu Wang, Xuerong Deng, Yan Geng, Zhuoli Zhang
doi : 10.1093/rheumatology/keac225
Rheumatology, Volume 62, Issue 1, January 2023, Pages 181–189
To assess the risk of flare in systemic lupus erythematosus (SLE) patients after low-dose glucocorticoid (GC) discontinuation and to evaluate the risk factors of flare.
Fibromyalgia, mood disorders, cognitive test results, cognitive symptoms and quality of life in systemic lupus erythematosus
Sudha Raghunath, Emma K Guymer, Yifat Glikmann-Johnston, Vera Golder, Rangi Kandane Rathnayake, Eric F Morand, Julie C Stout, Alberta Hoi
doi : 10.1093/rheumatology/keac207
Rheumatology, Volume 62, Issue 1, January 2023, Pages 190–199
Cognitive dysfunction, and comorbidities such as mood disorder and fibromyalgia, are common in SLE. This study aims to explore the associations between fibromyalgia, mood disorders, cognitive symptoms and cognitive dysfunction in SLE patients, and their impact on quality of life.
Survival analysis of mortality and development of lupus nephritis in patients with systemic lupus erythematosus up to 40 years of follow-up
Weike Luo, Filipa Farinha, David A Isenberg, Anisur Rahman
doi : 10.1093/rheumatology/keac218
Rheumatology, Volume 62, Issue 1, January 2023, Pages 200–208
Patients with SLE have increased mortality compared with age- and sex-matched controls. LN is a severe manifestation of SLE and an important cause of death. We carried out a retrospective survival analysis to investigate factors that could influence the risk of mortality and LN in a large multi-ethnic cohort of patients with SLE.
Major determinants of prolonged remission in systemic lupus erythematosus: retrospective study over a 41+ year period
Goncalo Durao-Carvalho, Raquel Fern?ndez-Gonz?lez, Bethan Goulden, Filipa Farinha, David Isenberg
doi : 10.1093/rheumatology/keac242
Rheumatology, Volume 62, Issue 1, January 2023, Pages 209–216
To investigate predictors of sustained complete remission (CR) for 3 and 5?years, minimum.
Clinical characteristics and risk factors associated with lymphoma in patients with systemic lupus erythematosus: a nationwide cohort study
Mar?a Mart?n-L?pez, Maria Galindo, José Mar?a Pego-Reigosa, Norman Jiménez, Alejandro Olivé Marqués, Eva Tomero, Mercedes Freire, Julia Mart?nez-Barrio, Alina Boteanu, Eva Salgado-Perez, Antonio Fern?ndez-Nebro, Jaime Calvo, Raul Menor-Almagro, I?igo R?a-Figueroa
doi : 10.1093/rheumatology/keac258
Rheumatology, Volume 62, Issue 1, January 2023, Pages 217–224
To assess the characteristics and risk of lymphoma in a large cohort of patients with SLE.
Extent of vascular plaque predicts future cardiovascular events in patients with systemic lupus erythematosus
Jyoti Bakshi, Sara C Croca, Maura Griffin, Filipa Farinha, David A Isenberg, Andrew Nicolaides, Anisur Rahman
doi : 10.1093/rheumatology/keac259
Rheumatology, Volume 62, Issue 1, January 2023, Pages 225–233
Patients with SLE have increased prevalence of clinical cardiovascular disease (CVD) and subclinical atherosclerosis. Although 30–40% of patients with SLE have vascular plaque on ultrasound scanning, this study is the first to consider the relationship between total burden of plaque and subsequent CVD risk.
Biological and clinical insights from a randomized phase 2 study of an anti-oncostatin M monoclonal antibody in systemic sclerosis
Christopher P Denton, Francesco del Galdo, Dinesh Khanna, Madelon C Vonk, Lorinda Chung, Sindhu R Johnson, John Varga, Daniel E Furst, Jane Temple, Chiara Zecchin, Eszter Csomor, Amy Lee, Nicolas Wisniacki, Shaun M Flint, Juliet Reid
doi : 10.1093/rheumatology/keac300
Rheumatology, Volume 62, Issue 1, January 2023, Pages 234–242
The cytokine oncostatin M (OSM) is implicated in the pathology of SSc. Inhibiting OSM signalling using GSK2330811 (an anti-OSM monoclonal antibody) in patients with SSc has the potential to slow or stop the disease process.
Characterization and outcomes of 414 patients with primary SS who developed haematological malignancies
Gabriela Hern?ndez-Molina, Belchin Kostov, Pilar Brito-Zer?n, Arjan Vissink, Thomas Mandl, Anneline C Hinrichs, Luca Quartuccio, Chiara Baldini, Raphaele Seror, Antonia Sz?nt?, David Isenberg, Roberto Gerli, Gunnel Nordmark, Astrid Rasmussen, Roser Solans-Laque, Benedikt Hofauer, Damien Sène, Sandra G Pasoto, Maureen Rischmueller, Sonja Praprotnik, Tamer A Gheita, Debashish Danda, Berkan Arma?an, Yasunori Suzuki, Valeria Valim, Valerie Devauchelle-Pensec, Soledad Retamozo, Marika Kvarnstrom, Agata Sebastian, Fabiola Atzeni, Roberto Giacomelli, Steven E Carsons, Seung-Ki Kwok, Hideki Nakamura, Virginia Fernandes Moça Trevisani, Alejandra Flores-Ch?vez, Xavier Mariette, Manuel Ramos-Casals, the Sj?gren Big Data Consortium
doi : 10.1093/rheumatology/keac205
Rheumatology, Volume 62, Issue 1, January 2023, Pages 243–255
To characterize 414 patients with primary SS who developed haematological malignancies and to analyse how the main SS- and lymphoma-related features can modify the presentation patterns and outcomes.
Thrombocytopenia in primary antiphospholipid syndrome: association with prognosis and clinical implications
Yu Shi, Jiuliang Zhao, Hui Jiang, Can Huang, Wanting Qi, Yijun Song, Qian Wang, Mengtao Li, Xinping Tian, Yongqiang Zhao, Xiaofeng Zeng
doi : 10.1093/rheumatology/keac264
Rheumatology, Volume 62, Issue 1, January 2023, Pages 256–263
Thrombocytopenia, a frequent clinical manifestation in patients with APS, could be an independent predictor of recurrent thrombotic, obstetric and severe extracriteria events.
Pain profile and opioid medication use in patients with idiopathic inflammatory myopathies
Abhiram Bhashyam, Manuel Lubinus, Emily Filmore, Lynn Wilson, Jerry Williams, Osniel Gonzalez Ramos, Salman Bhai
doi : 10.1093/rheumatology/keac271
Rheumatology, Volume 62, Issue 1, January 2023, Pages 264–269
Pain is commonly reported in people living with myositis. This study assesses the presence of pain in the subtypes of myositis as well as the frequency of opioid and non-opioid pain medication use.
Patterns of body composition and alteration after treatment in patients with newly diagnosed idiopathic inflammatory myopathies
Shiyi Yang, Cheng Luo, Wei Zheng, Xue Li, Xu Zhang, Ying Jiang, Fei Xiao
doi : 10.1093/rheumatology/keac286
Rheumatology, Volume 62, Issue 1, January 2023, Pages 270–280
To define the pattern of body composition and alteration after treatment of patients with newly diagnosed idiopathic inflammatory myopathies (IIMs) using DXA.
Cancer and immune-mediated necrotizing myopathy: a longitudinal referral case-controlled outcomes evaluation
Shahar Shelly, Grayson Beecher, Margherita Milone, Teerin Liewluck, Floranne Ernste, James Triplett, Elie Naddaf, Anastasia Zekeridou, Andrew McKeon, Sean J Pittock, Divyanshu Dubey, John R Mills, Jay Mandrekar, Christopher J Klein
doi : 10.1093/rheumatology/keac144
Rheumatology, Volume 62, Issue 1, January 2023, Pages 281–289
To investigate immune-mediated necrotizing myopathy (IMNM) association with cancer and its clinical implications.
Performance of timed function tests as outcome measures in idiopathic inflammatory myopathy—results from a single-centre cohort
Saikumar Dunga, Chengappa Kavadichanda, Devender Bairwa, Molly Mary Thabah, Vir Singh Negi
doi : 10.1093/rheumatology/keac244
Rheumatology, Volume 62, Issue 1, January 2023, Pages 290–299
To evaluate performance of timed function tests (TFTs) in assessing muscle strength and endurance as determined by Manual Muscle Testing 8 (MMT-8) and Functional Index 2 (FI-2), respectively, in idiopathic inflammatory myopathies (IIM).
Ultrasound and MR muscle imaging in new onset idiopathic inflammatory myopathies at diagnosis and after treatment: a comparative pilot study
Anne W Walter, Johan Lim, Joost Raaphorst, Frank F Smithuis, J Michiel den Harder, Filip Eftimov, Wouter Potters, Christiaan G J Saris, Marianne de Visser, Ivo N van Schaik, Rob J de Haan, Anneke J van der Kooi, Camiel Verhamme
doi : 10.1093/rheumatology/keac263
Rheumatology, Volume 62, Issue 1, January 2023, Pages 300–309
To prospectively compare ultrasound (US) and whole-body MRI for detection of muscle abnormalities compatible with idiopathic inflammatory myopathies (IIM).
Thigh MRI in antisynthetase syndrome, and comparisons with dermatomyositis and immune-mediated necrotizing myopathy
Wenhao Zhang, Yiming Zheng, Yikang Wang, Hui Xiong, Chengli Que, Xiaohui Zhang, Ying Zhu, Yawen Zhao, Meng Yu, Lingchao Meng, He Lv, Wei Zhang, Hongjun Hao, Jiangxi Xiao, Yun Yuan, Zhaoxia Wang
doi : 10.1093/rheumatology/keac269
Rheumatology, Volume 62, Issue 1, January 2023, Pages 310–320
To evaluate MRI changes to define muscle-lesion specific patterns in patients with antisynthetase syndrome (ASS), and compare them with those in other common idiopathic inflammatory myopathy subtypes.
Cytokine profile, ferritin and multi-visceral involvement characterize macrophage activation syndrome during adult-onset Still’s disease
Piero Ruscitti, Francesco Ursini, Onorina Berardicurti, Francesco Masedu, Emanuele Bozzalla Cassione, Susanna Naldi, Ilenia Di Cola, Claudia Di Muzio, Ludovico De Stefano, Elena Di Nino, Luca Navarini, Marta Vomero, Serena Bugatti, Marco Valenti, Erminia Mariani, Annamaria Iagnocco, Carlomaurizio Montecucco, Roberto Giacomelli, Paola Cipriani
doi : 10.1093/rheumatology/keac247
Rheumatology, Volume 62, Issue 1, January 2023, Pages 321–329
To multidimensionally characterize macrophage activation syndrome (MAS) complicating adult-onset Still’s disease (AOSD) considering cytokine profile, inflammatory markers and multi-visceral involvement of the disease. To perform a high-dimensional phenotypic analysis of circulating immune cells in AOSD patients with and without MAS.
Rituximab dose-dependent infection risk in rheumatoid arthritis is not mediated through circulating immunoglobulins, neutrophils or B cells
Merel A A Opdam, J H de Leijer, Nathan den Broeder, Rogier M Thurlings, Wilfred van der Weele, Michael T Nurmohamed, Marc R Kok, Lenny van Bon, David F Ten Cate, Lise M Verhoef, Alfons A den Broeder
doi : 10.1093/rheumatology/keac318
Rheumatology, Volume 62, Issue 1, January 2023, Pages 330–334
Rituximab (RTX) is a safe and effective treatment for RA. A dose-dependent infection risk was found in the REDO trial. Some studies associate RTX use with higher infection risks, possibly explained by low immunoglobulin levels and/or neutropenia.
Nailfold capillaroscopy: a survey of current UK practice and ‘next steps’ to increase uptake among rheumatologists
Martin Eden, Sarah Wilkinson, Andrea Murray, Praveen Gurunath Bharathi, Andy Vail, Chris J Taylor, Katherine Payne, Ariane L Herrick
doi : 10.1093/rheumatology/keac320
Rheumatology, Volume 62, Issue 1, January 2023, Pages 335–340
To identify barriers to the use of nailfold capillaroscopy as a diagnostic tool for patients presenting with Raynaud’s phenomenon in UK rheumatology centres and to obtain rheumatologists’ views on a proposed internet-based standardized system for clinical reporting of nailfold capillaroscopy images.
Use of biologics to treat relapsing and/or refractory polyarteritis nodosa: data from a European collaborative study
Jérome Hadjadj, Alice Canzian, Omer Karadag, Anne Contis, François Maurier, Sébastien Sanges, Silvia Sartorelli, Laure Denis, Claire de Moreuil, Cécile-Audrey Durel, Stéphane Durupt, Marie Jachiet, Diane Rouzaud, Carlo Salvarani, Roberto Padoan, Lorenzo Dagna, Fabrice Bonnet, Christian Agard, Thomas Moulinet, Marion Hermet, Raluca Sterpu, Alexandre Thibault Jacques Maria, Jérémy Keraen, Loic Guillevin, David Jayne, Benjamin Terrier
doi : 10.1093/rheumatology/keac332
Rheumatology, Volume 62, Issue 1, January 2023, Pages 341–346
To describe the effectiveness and safety of biologics for the treatment of relapsing and/or refractory polyarteritis nodosa (PAN).
Case report and review of the literature: immune dysregulation in a large familial cohort due to a novel pathogenic RELA variant
Kelsey Lecerf, Daniel C Koboldt, Hye Sun Kuehn, Vijayakumar Jayaraman, Kristy Lee, Theresa Mihalic Mosher, Jennifer R Yonkof, Mari Mori, Scott E Hickey, Samuel Franklin, Joanne Drew, Shoghik Akoghlanian, Vidya Sivaraman, Sergio D Rosenzweig, Richard K Wilson, Roshini S Abraham
doi : 10.1093/rheumatology/keac227
Rheumatology, Volume 62, Issue 1, January 2023, Pages 347–359
To explore and define the molecular cause(s) of a multi-generational kindred affected by Bechet’s-like mucocutaneous ulcerations and immune dysregulation.
Mutation in the CCAL1 locus accounts for bidirectional process of human subchondral bone turnover and cartilage mineralization
Alejandro Rodr?guez Ruiz, Marcella van Hoolwerff, Sara Sprangers, Eka Suchiman, Ton Schoenmaker, Petra Dibbets-Schneider, Johan L Bloem, Rob G H H Nelissen, Christian Freund, Christine Mummery, Vincent Everts, Teun J de Vries, Yolande F M Ramos, Ingrid Meulenbelt
doi : 10.1093/rheumatology/keac232
Rheumatology, Volume 62, Issue 1, January 2023, Pages 360–372
To study the mechanism by which the readthrough mutation in TNFRSF11B, encoding osteoprotegerin (OPG) with additional 19 amino acids at its C-terminus (OPG-XL), causes the characteristic bidirectional phenotype of subchondral bone turnover accompanied by cartilage mineralization in chondrocalcinosis patients.
MDA5 expression is associated with TGF-?-induced fibrosis: potential mechanism of interstitial lung disease in anti-MDA5 dermatomyositis
Ning Shen, Xiaopeng Zhou, Xuexiao Jin, Ci Lu, Xiuhua Hu, Yichi Zhang, Yu Jiang, Qin Xu, Xiayan Xu, Minghao Liu, Linrong Lu, Yongmei Han
doi : 10.1093/rheumatology/keac234
Rheumatology, Volume 62, Issue 1, January 2023, Pages 373–383
This study aimed to investigate the high-resolution CT (HRCT) characteristics of anti-melanoma differentiation-associated gene 5 (MDA5) antibody positive dermatomyositis-associated interstitial lung disease (anti-MDA5 DM-ILD), and to clarify the underlying mechanisms of the clinical phenomenon.
SNP rs7130280 in lncRNA NONHSAT159216.1 confers susceptibility to Behçet’s disease uveitis in a Chinese Han population
Jun Zhang, Jian Qi, Jia Shu, Guannan Su, Qingfeng Cao, Chunjiang Zhou, Yao Wang, Peizeng Yang
doi : 10.1093/rheumatology/keac230
Rheumatology, Volume 62, Issue 1, January 2023, Pages 384–396,
Long noncoding RNA (lncRNA) plays a crucial role in the process of immune-mediated diseases. However, the defined involvement of lncRNA on Behçet’s disease (BD) is not well known.
Evaluation and validation of the prognostic value of anti-MDA5 IgG subclasses in dermatomyositis-associated interstitial lung disease
Yue-Tong Xu, Ya-Mei Zhang, Hong-Xia Yang, Li-Fang Ye, Fang Chen, Xin Lu, Guo-Chun Wang, Qing-Lin Peng
doi : 10.1093/rheumatology/keac229
Rheumatology, Volume 62, Issue 1, January 2023, Pages 397–406
To investigate the association between the anti-melanoma differentiation associated gene 5 (MDA5) IgG subclasses and prognosis of patients with dermatomyositis (DM)-associated interstitial lung disease (ILD).
In rheumatoid arthritis patients, total IgA1 and IgA2 levels are elevated: implications for the mucosal origin hypothesis
Veerle F A M Derksen, Cornelia F Allaart, Annette H M Van der Helm-Van Mil, Tom W J Huizinga, René E M Toes, Diane van der Woude
doi : 10.1093/rheumatology/keac237
Rheumatology, Volume 62, Issue 1, January 2023, Pages 407–416
Mucosal initiated immune responses may be involved in the pathophysiology of RA. The most abundant immunoglobulin at mucosal surfaces is IgA, of which two subclasses exist: IgA1 and IgA2.
Phenotypic, transcriptomic and functional profiling reveal reduced activation thresholds of CD8+ T cells in giant cell arteritis
Rosanne D Reitsema, Kornelis S M van der Geest, Maria Sandovici, William F Jiemy, Jacoba C Graver, Wayel H Abdulahad, Annemieke M H Boots, Peter Heeringa, Elisabeth Brouwer
doi : 10.1093/rheumatology/keac250
Rheumatology, Volume 62, Issue 1, January 2023, Pages 417–427
Evidence from temporal artery tissue and blood suggests involvement of CD8+ T cells in the pathogenesis of GCA, but their exact role is poorly understood. Therefore, we performed a comprehensive analysis of circulating and lesional CD8+ T cells in GCA patients.
Digital image analysis of intraepithelial B-lymphocytes to assess lymphoepithelial lesions in salivary glands of Sj?gren’s syndrome patients
Martha S van Ginkel, Tineke van der Sluis, Marian L C Bulthuis, Henk J Buikema, Erlin A Haacke, Suzanne Arends, Stine Harder, Fred K L Spijkervet, Hendrika Bootsma, Arjan Vissink, Frans G M Kroese, Bert van der Vegt
doi : 10.1093/rheumatology/keac212
Rheumatology, Volume 62, Issue 1, January 2023, Pages 428–438
Salivary glands of primary SS (pSS) patients characteristically harbour periductal infiltrates, in which lymphoepithelial lesions (LELs) can develop.
Longitudinal association of infrapatellar fat pad signal intensity alteration with biochemical biomarkers in knee osteoarthritis
Han Cen, Qingran Yan, Weiyu Han, Tao Meng, Zhongshan Chen, Guangfeng Ruan, Tian Wang, Feng Pan, Di Chen, Virginia Byers Kraus, David J Hunter, Changhai Ding
doi : 10.1093/rheumatology/keac214
Rheumatology, Volume 62, Issue 1, January 2023, Pages 439–449
To explore the longitudinal association of quantitative infrapatellar fat pad (IPFP) signal intensity alteration with OA-related biomarkers.
Whole blood drug levels do not correlate with QTc intervals in hydroxychloroquine-treated systemic lupus erythematosus patients
H Michael Belmont, Mayce Haj-Ali
doi : 10.1093/rheumatology/keac245
Rheumatology, Volume 62, Issue 1, January 2023, Pages 450–456
HCQ is recommended for all patients with SLE, but reports of cardiac toxicity in severe acute respiratory syndrome coronavirus 2 patients raised concerns. We aimed to study the relationship between HCQ blood levels and QTc intervals.
Inhibiting thyroid activation in aged human explants prevents mechanical induced detrimental signalling by mitigating metabolic processes
Evelyn Houtman, Margo Tuerlings, H Eka D Suchiman, Nico Lakenberg, Frederique M F Cornelis, Hailiang Mei, Demiën Broekhuis, Rob G H H Nelissen, Rodrigo Coutinho de Almeida, Yolande F M Ramos, Rik J Lories, Luis J Cruz, Ingrid Meulenbelt
doi : 10.1093/rheumatology/keac202
Rheumatology, Volume 62, Issue 1, January 2023, Pages 457–466
To investigate whether the deiodinase inhibitor iopanoic acid (IOP) has chondroprotective properties, a mechanical stress induced model of human aged explants was used to test both repeated dosing and slow release of IOP.
Low incidence and transient elevation of autoantibodies post mRNA COVID-19 vaccination in inflammatory arthritis
Rebecca B Blank, Rebecca H Haberman, Kun Qian, Marie Samanovic, Rochelle Castillo, Anthony Jimenez Hernandez, Parvathy Vasudevapillai Girija, Sydney Catron, Zakwan Uddin, Paula Rackoff, Gary Solomon, Natalie Azar, Pamela Rosenthal, Peter Izmirly, Jonathan Samuels, Brian Golden, Soumya Reddy, Mark J Mulligan, Jiyuan Hu, Jose U Scher
doi : 10.1093/rheumatology/keac322
Rheumatology, Volume 62, Issue 1, January 2023, Pages 467–472
Autoantibody seroconversion has been extensively studied in the context of COVID-19 infection but data regarding post-vaccination autoantibody production is lacking.
Mosaic variants in TNFRSF1A: an emerging cause of tumour necrosis factor receptor-associated periodic syndrome
Eman Assrawi, Camille Louvrier, Elma El Khouri, Jérémie Delaleu, Bruno Copin, Florence Dastot-Le Moal, William Piterboth, Marie Legendre, Sonia A Karabina, Gilles Grateau, Serge Amselem, Irina Giurgea
doi : 10.1093/rheumatology/keac274
Rheumatology, Volume 62, Issue 1, January 2023, Pages 473–479
To identify the molecular basis of a systemic autoinflammatory disorder (SAID) evocative of TNF receptor-associated periodic syndrome (TRAPS).
Strong response after fourth dose of mRNA COVID-19 vaccine in autoimmune rheumatic diseases patients with poor response to inactivated vaccine
Nadia E Aikawa, Leonard V K Kupa, Clovis A Silva, Carla G S Saad, Sandra G Pasoto, Emily F N Yuki, Solange R G Fusco, Samuel K Shinjo, Danieli C O Andrade, Percival D Sampaio-Barros, Rosa M R Pereira, Anna C S Chasin, Andrea Y Shimabuco, Ana P Luppino-Assad, Elaine P Leon, Marta H Lopes, Leila Antonangelo, Ana C Medeiros-Ribeiro, Eloisa Bonfa
doi : 10.1093/rheumatology/keac301
Rheumatology, Volume 62, Issue 1, January 2023, Pages 480–485
To assess immunogenicity of a heterologous fourth dose of an mRNA (BNT162b2) severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine in autoimmune rheumatic diseases (ARD) patients with poor/non-response to inactivated vaccine (Sinovac-CoronaVac).
Correction to: Phase 2, randomized, placebo-controlled trial of dapirolizumab pegol in patients with moderate-to-severe active systemic lupus erythematosus
doi : 10.1093/rheumatology/keac326
Rheumatology, Volume 62, Issue 1, January 2023, Page 486
Correction
doi : 10.1093/rheumatology/keac368
Rheumatology, Volume 62, Issue 1, January 2023, Page 487
Upadacitinib response rates in patients with psoriatic arthritis enrolled in the SELECT-PsA-1 and SELECT-PsA-2 trials assessed according to modified PsARC
Laura C Coates, Toby Garrood, Nicola Gullick, Philip Helliwell, Toby Kent, Jonathan Marks, William Tillett, Daljit Kaur-Papadakis, Hasan Tahir, Stijn van Haaren, Iain McInnes
doi : 10.1093/rheumatology/keac388
Rheumatology, Volume 62, Issue 1, January 2023, Pages e1–e3
Effecter Th17-like regulatory T cells associate with the pathogenesis of rheumatoid arthritis
Kotona Furuyama, Yuya Kondo, Shunta Kaneko, Masaru Shimizu, Reona Tanimura, Hiroto Tsuboi, Takayuki Sumida, Isao Matsumoto
doi : 10.1093/rheumatology/keac382
Rheumatology, Volume 62, Issue 1, January 2023, Pages e4–e6,
Influence of HLA polymorphisms on clinical features of VEXAS syndrome: a potential epistatic mechanism
Bruno Lucchino, Annacarla Finucci, Francesco Ghellere, Maria Elena Bortolotti, Andrea Tedesco, Sara Lombardi
doi : 10.1093/rheumatology/keac371
Rheumatology, Volume 62, Issue 1, January 2023, Pages e7–e8
Cholinergic dysautonomia in a patient with systemic lupus erythematosus
Qi Liu, Yuxian Zhang, Hongqin Lu, Peng Yan, Xue Bai, Lili Cao, Xiuli Zuo, Chao Liu, Qiang Shu
doi : 10.1093/rheumatology/keac373
Rheumatology, Volume 62, Issue 1, January 2023, Pages e9–e11
Comment on: The neglected and untreated pains of CRMO and SAPHO syndrome
Anne T Leerling, Elizabeth M Winter
doi : 10.1093/rheumatology/keac236
Rheumatology, Volume 62, Issue 1, January 2023, Pages e12–e13
Comment on: The neglected and untreated pains of CRMO and SAPHO syndrome: reply
Praisoody Sinnappurajar, Marion Roderick, Athimalaipet V Ramanan
doi : 10.1093/rheumatology/keac238
Rheumatology, Volume 62, Issue 1, January 2023, Page e14,
Hypertrophic pachymeningitis in anti-neutrophil cytoplasmic antibody-associated vasculitis detected by 67Gallium scintigraphy
Hironori Inoue, Takashi Kida, Shunya Kaneshita, Yutaka Kawahito
doi : 10.1093/rheumatology/keac395
Rheumatology, Volume 62, Issue 1, January 2023, Page e15
